SARS

SARS is identified in the supplied sources as a severe acute respiratory syndrome caused by SARS-CoV-1, a coronavirus that produced the first documented acute epidemic in humans ^[1]. The disease is framed in the review literature as a priority pathogen because of the possibility of re-emergence ^[1]. The payload also records SARS under the viral category and assigns ICD-10 U04 and ICD-11 1D65 in the structured metadata, but no additional etiologic characterization is provided in the snippets beyond the SARS-CoV-1 association ^[1].

The review literature describes SARS as a disease with high lethality, reporting a case-fatality ratio of 10.9% in the extracted parameter set ^[1]. Severe disease and death were associated with age and existing comorbidities in the reviewed studies ^[1]. The same source notes that the natural history was poorly characterised overall, except for incubation and mean onset-to-hospitalisation delays, and the provided snippets do not supply further source-backed detail on symptom pattern, complications, or recovery course ^[1].

The supplied review identifies SARS as a transmissible epidemic disease with an estimated R0 range of 1.1 to 4.59 across the reviewed literature ^[1]. It also highlights superspreading, stating that approximately 91% of SARS-CoV-1 infections can be attributed to 20% of the most infectious individuals ^[1]. Infection risk was reported to be highest among health-care workers and close contacts of infected individuals, and the pathogen is described as remaining a priority because of re-emergence risk ^[1]. No further source-backed geographic distribution, current burden, or reservoir detail is available in the provided material ^[1].

The available source material supports transmission as person-to-person spread reflected in the elevated risk among close contacts of infected individuals and the role of highly infectious individuals in superspreading events ^[1]. The review focuses on transmission parameters rather than a single route, and the snippets do not specify respiratory droplets, aerosols, fomites, or other mechanisms ^[1]. Source-backed detail on environmental persistence or non-human exposure routes is not yet available in the provided payload ^[1].

The source-backed higher-risk groups identified in the review are health-care workers and close contacts of infected individuals ^[1]. Severe disease and death were associated with age and existing comorbidities in the reviewed studies ^[1]. No additional risk-group detail is supported by the supplied snippets ^[1].

The provided sources do not describe a specific prevention schedule or named control package for SARS. They do indicate that robust epidemiological parameter estimates are essential to guide outbreak responses and inform mathematical models, which supports surveillance-based preparedness and response planning ^[1]. On the basis of the supplied material, source-backed detail on vaccination, chemoprophylaxis, or other specific preventive measures is not yet available ^[1].

In surveillance contexts, SARS should be read as a re-emergence-prone coronavirus disease with documented epidemic potential, notable transmissibility, and substantial lethality in the reviewed evidence ^[1]. The strongest monitoring signals in the provided material are severe outcomes, clustering among health-care workers and close contacts, and the possibility of superspreading, which together imply the value of rapid case finding and exposure-linked investigation ^[1]. The source review also suggests that parameter estimation remains important because the natural history is incompletely characterised in the available literature ^[1].

1. 1 Morgenstern C et al. Severe acute respiratory syndrome (SARS) mathematical models and disease parameters: a systematic review. Lancet Microbe. 2025 Sep. PMID: 40713974. doi: 10.1016/j.lanmic.2025.101144. PubMed: https://pubmed.ncbi.nlm.nih.gov/40713974/
2. 2 Tossetta G et al. Preeclampsia and severe acute respiratory syndrome coronavirus 2 infection: a systematic review. J Hypertens. 2022 Sep 1. PMID: 35943095. doi: 10.1097/HJH.0000000000003213. PubMed: https://pubmed.ncbi.nlm.nih.gov/35943095/
3. 3 Minelli C et al. Brazilian practice guidelines for stroke rehabilitation: Part II. Arq Neuropsiquiatr. 2022 Jul. PMID: 36254447. doi: 10.1055/s-0042-1757692. PubMed: https://pubmed.ncbi.nlm.nih.gov/36254447/
4. 4 迎向风暴SARS — 再探非典型肺炎. Scholarly DOI record. 2003. doi: 10.1142/5360. DOI: https://doi.org/10.1142/5360
5. 5 神秘风暴SARS — 非典型肺炎初探（繁体）. Scholarly DOI record. 2003. doi: 10.1142/5324. DOI: https://doi.org/10.1142/5324
6. 6 SARS-Coronavirus (SARS-CoV). Lexikon der Infektionskrankheiten des Menschen. 2009. doi: 10.1007/978-3-540-39026-8_985. DOI: https://doi.org/10.1007/978-3-540-39026-8_985

ICD-10

U04

ICD-11

1D65

Total cases

2K

Peak month

2003-04

Coverage

5 reporting countries · 2010-01-01 → 2003-12-01